Therefore, this study clearly indicates that TRIM38 is a novel suppressor in NAFLD progression and targeting TRIM38 represents a promising therapeutic strategy for NAFLD. Here, TRIM38 is linked to metabolic dysfunction-associated steatotic liver disease.